Cancer Research UK, Cancer Therapeutics Unit, the Institute of Cancer Research London, Sutton, UK.
Fraunhofer ITMP ScreeningPort, Hamburg, Germany.
Autophagy. 2022 Mar;18(3):473-495. doi: 10.1080/15548627.2021.1936359. Epub 2021 Jul 9.
Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing cytosolic aggregated proteins, damaged organelles or invading microorganisms. Dysfunctional autophagy leads to pathological accumulation of the cargo, which has been linked to a range of human diseases, including neurodegenerative diseases, infectious and autoimmune diseases and various forms of cancer. Cumulative work in animal models, application of genetic tools and pharmacologically active compounds, has suggested the potential therapeutic value of autophagy modulation in disease, as diverse as Huntington, infection, or pancreatic cancer. Autophagy activation versus inhibition strategies are being explored, while the role of autophagy in pathophysiology is being studied in parallel. However, the progress of preclinical and clinical development of autophagy modulators has been greatly hampered by the paucity of selective pharmacological agents and biomarkers to dissect their precise impact on various forms of autophagy and cellular responses. Here, we summarize established and new strategies in autophagy-related drug discovery and indicate a path toward establishing a more efficient discovery of autophagy-selective pharmacological agents. With this knowledge at hand, modern concepts for therapeutic exploitation of autophagy might become more plausible.: ALS: amyotrophic lateral sclerosis; AMPK: AMP-activated protein kinase; ATG: autophagy-related gene; AUTAC: autophagy-targeting chimera; CNS: central nervous system; CQ: chloroquine; GABARAP: gamma-aminobutyric acid type A receptor-associated protein; HCQ: hydroxychloroquine; LYTAC: lysosome targeting chimera; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NDD: neurodegenerative disease; PDAC: pancreatic ductal adenocarcinoma; PE: phosphatidylethanolamine; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: class III phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol 3-phosphate; PROTAC: proteolysis-targeting chimera; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SQSTM1/p62: sequestosome 1; ULK1: unc-51 like autophagy activating kinase 1.
自噬是一种进化上保守的途径,负责清除细胞质中聚集的蛋白质、受损的细胞器或入侵的微生物。自噬功能障碍导致货物的病理性积累,这与一系列人类疾病有关,包括神经退行性疾病、感染和自身免疫性疾病以及各种形式的癌症。在动物模型中的累积工作、遗传工具的应用和具有药理活性的化合物的应用,表明自噬调节在亨廷顿氏病、感染或胰腺癌等多种疾病中的潜在治疗价值。正在探索自噬的激活与抑制策略,同时也在研究自噬在病理生理学中的作用。然而,自噬调节剂的临床前和临床开发进展受到缺乏选择性药理制剂和生物标志物的极大阻碍,无法剖析它们对各种形式的自噬和细胞反应的确切影响。在这里,我们总结了自噬相关药物发现的现有和新策略,并指出了建立更有效的自噬选择性药理制剂发现的途径。有了这些知识,自噬治疗利用的现代概念可能变得更加合理。: ALS: 肌萎缩性侧索硬化症; AMPK: AMP 激活的蛋白激酶; ATG: 自噬相关基因; AUTAC: 自噬靶向嵌合体; CNS: 中枢神经系统; CQ: 氯喹; GABARAP: γ-氨基丁酸 A 型受体相关蛋白; HCQ: 羟氯喹; LYTAC: 溶酶体靶向嵌合体; MAP1LC3/LC3: 微管相关蛋白 1 轻链 3; MTOR: 雷帕霉素靶蛋白激酶; NDD: 神经退行性疾病; PDAC: 胰腺导管腺癌; PE: 磷脂酰乙醇胺; PIK3C3/VPS34: 磷脂酰肌醇 3-激酶催化亚单位 3; PtdIns3K: 类 III 磷脂酰肌醇 3-激酶; PtdIns3P: 磷脂酰肌醇 3-磷酸; PROTAC: 蛋白水解靶向嵌合体; SARS-CoV-2: 严重急性呼吸综合征冠状病毒 2; SQSTM1/p62: 自噬相关蛋白 1; ULK1: 非典型蛋白激酶 1。